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Got "Hormone-Free" Milk?: Your State
May Have Enough Interest to
Let You Know
JENNIFER R. THORNLEY
INTRODUCTION
The food we consume and the milk we drink are affected by our world's search for
new technology to produce more at a lower cost. Food manufacturers and drug
companies have undertaken the controversialpractice ofgenetically engineering food
and artificially imitating natural processes of animals in order to produce a bigger
tomato, allow corn to naturally ward off pests, and increase a cow's lactation.
Sometimes, however, technology thrusts us into the world of the unknown and
advancements may come at a price uncalculated orunnoticed by all--especiallywhen
toying with Mother Nature herself. Although there is much to be said about
genetically engineered foods and the technology used, the focus of this Note is on the
use of Recombinant Bovine Somatotropin Hormone ("rBST"), a hormone injected
into cows to increase milk production.
The somatotropin hormone exists naturally in the pituitary glands of a cow and
controls the cow's ability to lactate.' Monsanto, a large American drug company,
created a synthetic form of this hormone and, after the U.S. Food and Drug
Administration's ("FDA") approval of its use in 1993,? began distributing the drug
to the dairy industry in America under the name Posilac.3 Posilac is estimated to
increase a cow's production of milk between seventeen4 and forty percent' per day.
Some criticize the use of the hormone for its possible link to increased pus
production, shorter life-span, and diseases like mastitis6 in cows.7 There is also
controversy surrounding the studies conducted on the effects consumption of milk
from a cow treated with rBST has on human health.
* J.D. Candidate, 2001, Indiana University School of Law-Bloomington; B.S., 1995,
Indiana University-Bloomington. I would like to thank Matt Lamkin, my family, and Julia
Butterfly Hill for their love, support, and commitment to making the world a better place for
all living things.
I. Kristine Cerro, Comment, High-Tech Cows: The BST Controversy, 6 SAN JOAQUIN
AGRIC. L. REv. 163, 164-65 (1996) (citing BSTFact Sheet, NEWSCAST, Summer 1993, at 4).
2. Id. at 163.
3. Terence J. Centner & Kyle W. Lathrop, Labeling rBST-Derived Milk Products: State
Responses to Federal Law, 45 U. KAN. L. REv. 511,515 (1997).
4. See Bruce W. Marion & Robert L. Wills, A Prospective Assessment of the Impacts of
Bovine Somatotropin: A Case Study of Wisconsin, 72 AM. J. AGRIC. ECON. 326, 327 (1990).
5. David Aboulafia, Pushing RBST.. How the Law and the Political Process Were Used
to Sell Recombinant Bovine Somatotropin to America, 15 PACE ENVTL L. REv. 603, 605
(1998).
6. Mastitis is "an inflammation of the udder and is generally accepted as the most costly
and widespread disease of the dairy industry." Cerro, supra note 1, at 178 n. 117.
7. See Ben & Jerry's Thoughts About Bovine Growth Hormone (BGH), at
http://www.benjerry.com/bgh/index.html (last visited Apr. 3, 2001) (citing studies that report
aseventy-nine percent increase in mastitis, reduced pregnancy rates, cystic ovaries, lacerations,
digestive disorders, and calluses of the knee) [hereinafter Ben & Jerry's].
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Not long after the FDA approved the use of rBST, companies and farmers
employed various labels on their dairyproducts indicating that their products did not
come from treated cows-instigating courtbattles between those manufacturers using
rBST and the dairy farmers using no hormones. In reaction to the confusion, the FDA
issued an interim opinion outlining the permissibility of farmers and grocery stores
labeling their dairy products and providing guidance on how to label legally and
appropriately.8 The guidelines provided that labeling occur on a voluntarybasis and
that all labels contain the following statement: "[N]o significant difference has been
shown between milk derived from rBST-treated and non-rBST-treated cows." The
FDA did not make any of the labeling mandatory and was not clear initially on
whether they permitted mandatory labeling laws-leaving it up to the states to adopt
their own laws. Some states refused to allow labeling of any kind,"° others adopted
the voluntary labeling provided by the FDA's interim, and a few states attempted to
issue mandatory labeling laws." The one state to enact a mandatory labeling law,
Vermont, found itself in a court battle with dairy producers who were arguing an
infringement on their First Amendment rights to speak and not to speak. 2 While the
court ruled against Vermont, the two-judge majority left an evidentiary door
open-stating that with more evidence to support citizens' concern, Vermont maybe
able to establish successfully a substantial state interest and enact a mandatory
labeling law. 3
Part I of this Note will discuss the court case that struck down the mandatory
labeling law in Vermont and set forth the court's reasoning. Part II will assist
Vermont and other states wishing to pass mandatory labeling laws in walking through
the door left open by the court by providing new and compelling evidence that has
surfaced since the case was decided in 1996. This evidence includes new research
regarding the reactions of citizens to rBST, regulations ofrBST in other nations, new
concern over human health issues, ailegations and accusations regarding the
objectivity of the FDA, and evidence of bullying tactics by Monsanto. Part IT will
discuss the current stance other states are taking with regard to mandatory labeling.
Finally, this Note will conclude with suggestions regarding how Vermont and other
8. Interim Guidance on the Voluntary Labeling of Milk and Milk Products from Cows
That Have Not Been Treated with Recombinant Bovine Somatotropin, 59 Fed. Reg. 6279 (Feb.
10, 1994).
9. Biotechnology: Interim Voluntary Guidance on BST Issued by FDA for Milk
Producers, 17 Chemical Reg. Rep. (BNA) i916 (Feb. 11, 1994), WL 17 CHEM 1916.
10. Illinois was one such state until Ben & Jerry's, Inc. filed a lawsuit stating that their
constitutional rights were being infringed upon by Illinois's lawmaking the label "rBGH-free"
illegal to place on their products. Ben & Jerry's Homemade, Inc. v. Lumpkin, No. 96-C2748,
1996 U.S. Dist. LEXIS 12469, at *2 (N.D. I11. Aug. 27, 1996). The case settled with Illinois
allowing the voluntary labeling of food products and a compromise as to the language used on
the labels. Ben & Jerry's, State in Accord on Growth Hormone Statement, Ca. TRm., Aug. 14,
1997, at 4.
11. See VT. STAT. ANN. tit. 6, § 2754(c) (repealed 1998); Aboulafia, supra note 5, at 621-
22 (stating that attorney generals from New York, Wisconsin, and Texas all campaigned for
mandatory labeling laws).
12. See Int'l Dairy Foods Ass'n v. Amestoy, 92 F.3d 67 (2d Cir. 1996).
13. See id. at 74.
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states can be successful in defending such laws in court andwhytheir success matters
for consumers.
I. INTERNATIONAL DAIRYFOODSASs'N V. AMESTOyI4
In response to the overwhelming concern of its citizens following the approval and
use ofrBST, the Vermont state legislature passed a statute requiring the labeling of
food that contains or possibly contains dairy product from a cow injected with the
hormone. 5 The regulations promulgated pursuant to that statute required
manufacturers to place a blue dot on their products if anypart was froma treated cow
and required retailers to post a sign explaining that products with a blue dot "contain
or may contain milk fromrBST-treated cows."'6 In compliance with FDA guidelines,
Vermont regulations required the signs to state that "the [FDA] has determined that
there is no significant difference between milk from treated and untreated cows."'"
The regulations also stated that the sign must include that the labeling was required
by the State of Vermont in order to help "consumers make informed shopping
decisions.""
The International Dairy Foods Association ("IDFA") immediately retaliated by
taldng the State of Vermont to court, arguing that the statute was unconstitutional. 9
Vermont asserted that strong consumer concern regarding the effects of rBST on
cows and humans and the ability of its citizens to make informed choices about the
dairy products they buy led it to issue the mandatory labeling law. Vermont argued
that requiringlabels on dairyproducts was the most appropriate method for appeasing
consumer concerns and placing the decision about whether to consume milk from
cows treated with rBST where itbelongs-in the hands of the consumers. The district
court denied IDFA summary judgment, concluding that the State of Vermont had a
substantial interest in the concerns of its citizens regarding the use of rBST.20 The
appellate court reversed asserting that citizen concern and desire for labeling in order
to make choices as consumers (the two interests advanced by Vermont) were not
sufficient enough reasons for impeding on the commercial speech right "notto speak"
guaranteed by the Constitution. 2'
The appellate court followed the four prong test set out in Central Hudson Gas &
Electric Corp. v. Public Service Commissioner in order to evaluate the
14. 92 F.3d 67 (2d Cir. 1996).
15. VT. STAT. ANN. tit. 6, § 2754(c).
16. Amestoy, 92 F.3d at 70 (emphasis omitted) (quoting Adopted Rules: rBSTNotification
and Labeling Regulations Relating to Milk and Milk Products, Vt. Gov't Reg. § 3. l b (1995)).
17. Id. (quoting Adopted Rules: rBST Notification and Labeling Regulations Relating to
Milk and Milk Products, Vt. Gov't Reg. § 3.1b (1995)).
18. Id. (quoting Adopted Rules: rBST Notification and Labeling Regulations Relating to
Milk and Milk Products, Vt. Gov't Reg. § 3. lb (1995)).
19. Id.
20. Int'l Dairy Foods Ass'n v. Amestoy, 898 F. Supp. 246, 254 (D. Vt. 1995), rev'd, 92
F.3d 67 (2d Cir. 1996).
21. Amestoy, 92 F.3d at 71.
22. 447 U.S. 557 (1980).
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constitutionality of the statute in question.' The fourparts are (1) whether the speech
is commercial, (2) whether the government's interest is substantial, (3) whether the
labeling law directly serves the interest asserted by the government, and (4) whether
the labeling law is no more restrictive than necessary.24 The appellate court concluded
that, even though the speech was commercial in nature (a type of speech afforded less
protection under the First Amendment), Vermont had not satisfied the second prong
of the test-whether the government's interest is substantial.' The court engaged in
a balancing test in order to determine whether the second prong had been satisfied.'
The judges weighed the possible harmful effect labeling would have on the sale of
dairyproducts from treated cows against the interest Vermont citizens have in making
conscious choices about the products they buy.' Despite the fact that the district
court found enough evidence to support the consumer concern argument, 2 the
appellate court reversed in a 2-1 decision, dismissing the concern as mere
unsubstantiated "curiosity."
Judge Leval raised strong objections in his dissenting opinion that deserve
attention. He argued that the interests considered by the court in their balancing test
were a watered down version of the arguments Vermont advanced. The majority
determined that Vermont was requiring labeling solely because of consumer
curiosity.3 The majority failed, in Leval's opinion, to recognize all of the legitimate
reasons surrounding consumer concern and the desire to have labels in order to make
more informed choices. He offered examples of legitimate reasons for consumer
concern such as ethical and moral concerns regarding the health and well-being of
cows, effects on human health, skepticism surrounding the thoroughness and validity
of the FDA's approval, and the impact the use of rBST would have on small dairy
farmers.
32
Judge Leval also criticized the majority's use of the First Amendment to strike
down a state law mandating disclosure of information consumers reasonably want
when purchasing food items, stating that the outcome "stands the Amendment on its
ear.233 The First Amendment searches for truthful speech and the labels that Vermont
sought to mandate contained truthful and accurate information.34 Leval asserted that
the plaintiffs concern that it be forced to say something they did not believe, which
is unconstitutional under Wooley v. Maynard,5 is unfounded considering the precise
23. Id. at 562-63.
24. Id. at 566.
25. Amestoy, 92 F.3d at 73.
26. Id. at 72-74.
27. Id.
28. See Int'l Dairy Foods Ass'n v. Amestoy, 898 F. Supp. 246, 254 (D. Vt. 1995), rev'd,
92 F.3d 67 (2d Cir. 1996).
29. Amestoy, 92 F.3d at 73 n.l.
30. See id. at 76 (Leval, J., dissenting).
31. Id. at73 n.l.
32. Id. at 75-76 (Leval, J., dissenting). For purposes of this Note, the impact rBST use
would have on small dairy farmers will not be discussed in any kind of detail.
33. Id. at 74.
34. See id.
35. 430 U.S. 705, 714 (1977).
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language of the sign which recognized the FDA's findings of no harm" The sign
also attributed the labeling to Vermont's law in order to not mislead consumers into
thinking the manufacturers voluntarily labeled."'
The majority stated that the public's desire to know has never been found to be a
legitimate state interest with regard to speech?' Leval, after criticizing the majority's
failure to regard the district court's report containing all of the reasons and evidence
advanced by Vermont, pointed to several court cases in which this issue was
considered.39 In Liquormart, Inc. v. Rhode Island" the Supreme Court established
that, when concerning commercial speech, the interest protected by the First
Amendment is the "public's interest in receiving accurate commercial information."'
In that case, the Court struck down a state law that made liquor dealers' advertising
of prices illegal. The Court determined that when a state mandated the disclosure of
"beneficial consumer information, the purpose ofits regulation is consistent with the
reasons for according constitutional protection to commercial speech."'42 In his
concurring opinion, Justice Thomas stressed that an attempt to keep lawful consumers
ignorant in order to "manipulate their choices in the marketplace" is "per se
illegitimate."'
43
Leval asserted that the majority erred in not considering Vermont's interest in its
consumer concern substantial.4 He argued that the evidence and arguments produced
by Vermont were even stronger than those present in some cases in which the
Supreme Court found a substantial interest.45 He criticized the court's decision as
"depriv[ing] Vermont of the right to protect its consumers by requiring truthful
disclosure on a subject of legitimate public concern."
Although the majority found that Vermont did not provide enough evidence to
support its reasoning regarding public concern, Leval was comforted by the fact that
the door has been left open for Vermont to do just that-provide enough evidence to
win.'7 He also established that the court's findings have no bearing on any case in
which the state provides an interest in addition to the "gratification of consumer
curiosity.""49
As Judge Leval noted in his dissenting opinion, Vermonters and other consumers
36. Amestoy, 92 F.3d at 79-80 (Leval, J., dissenting).
37. See id.
38. Id. at 73.
39. See id. at 80-81 (Leval, 3., dissenting).
40. 517 U.S. 484 (1996).
41. Id. at 496.
42. Id. at 501.
43. Id. at 518 (Thomas, J., concurring).
44. Amestoy, 92 F.3d at 76 (Leval, J., dissenting).
45. !d. at 78 (comparing Florida Bar v. Went For It, Inc., 515 U.S. 618 (1995) (deeming
the state's interest in privacy and tranquility sufficient to uphold a thirty-day waiting period by
lawyers before solicitation of business from accident victims), with City of Cincinnati v.
DiscoveryNetwork, 507 U.S. 410 (1993) (establishing safety and aesthetics as substantial state
interests regarding a law regulating commercial handbill distribution on public property)).
46. Id. at 81.
47. See id.
48. Id.
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across the nation have a legitimate concern-Vermont and other states simply need
to advance these reasons thoroughly in court. As noted earlier, he offered four
reasons why consumers may wish to know whether the dairy products they eat come
from a treated cow.49 Judge Leval pointed out that with enough evidence, any one of
the four on its own can stand as a substantial interest' °
II. RECENT FINDINGS SINCE AMESTOY
The court in Amestoy decided in favor of the dairy industry on the grounds that
Vermont had not supplied enough evidence to substantiate its interest in consumer
concern." The court also stated that the evidence that Vermont could have presented
regarding the use ofrBST would not have been enough considering the "exhaustive
studies" the FDA had conducted.52 The court, therefore, placed considerable faith in
the FDA findings and had doubts that Vermont could have refuted them to the degree
necessary to render ajudgment in its favor. The district court and dissenting judge in
the appellate court concluded that enough evidence existed when the case was argued
before them. This Note proposes that even though Vermont may have provided
enough compelling evidence in 1995, significantly more research, studies, consumer
reactions, and reasons to doubt the FDA have developed since the holding.
A. Outside the United States
Perhaps the biggest additions to the debate of rBST since the Second Circuit
decided Amestoy are the recent decisions by Canada and the European Union to ban
the use of rBST 3 In August of 1994, the Canadian government postponed the sale
and use of rBST until July of 1995 to allow for sufficiently substantial testing in
order to ensure a well-informed public.' Health Canada (the FDA's Canadian
counterpart) continued to delay its approval and, in December of 1998, again declined
to permit the sale and use of the hormone, citing the need for more studies." In 1998,
a "leaked" report by scientists studying rBST for Health Canada revealed "numerous
gaps" in the FDA's data on human and animal safety.'
Health Canada is also concerned about the actions of their own regulatory agency
and the coercive behavior of Monsanto.Y Five Health Canada scientists testified
49. See supra text accompanying note 32.
50. Amestoy, 92 F.3d at 78 (Leval, L, dissenting).
51. See id. at 74.
52. Id. at 73.
53. Denmark, Sweden, Norway, the Netherlands, Australia, New Zealand, and Argentina
have also banned the sale and use ofrBST. Aboulafia, supra note 5, at 621.
54. See Canada Delays Introduction ofBST: Bovine Somatotropin, AGRA EuROPE, Aug.
19, 1994, atN3, 1994 WL 13042597.
55. See Emily Green, The SpudAmerica Didn't Like, NEW STATESMAN, Feb. 26, 1999, at
18, 18; see also Melinda Fulmer, Organic Milk Pours into Mainstream, L.A. TIMES, July 24,
1999, at Cl.
56. KellyMorris, Bovine Somatotropin-Who's CryingoverSpiltMilk?, 353 LANCET 306,
306 (1999).
57. See Laura Eggertson, Experts Raise Concerns over Cow Hormone, TORONTO STAR,
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about their fears to the Senate Agriculture Committee and accused Monsanto of
bullying tactics. "We have been pressured and coerced to pass drugs of questionable
safety, including rBST. That is our concern," stated Shiv Chopra, a veterinarian and
reviewer in Health Canada's Bureau of Veterinary Drugs." The scientists noted that
the files on rBST were under lock and key-accessible only through one official.'
The Canadian press has reported allegations regarding stolen files and a bribe by
Monsanto to the government for millions of dollars in exchange for approval of their
drug without further submissions to clinical trials, although these allegations have not
been entirely substantiated.6 These findings and questionable tactics continue to
convince the Canadian government that not enough is known about the effects of
using rBST in order to declare the drug safe. In January 1999, Canada officially
banned the use of rBST.62
Similarly, the European Union requested a moratorium in 1989 to research further
the effects that injecting rBST in dairy cows has on human and cow health.63 United
Kingdom officials declared animal welfare of "vital importance" to their farmers."
Contrary to initial statements by the FDA that rBST does not impact the incidence or
duration ofmastitis in cows,65 studies conducted by European scientists indicate that
injecting cows with rBST increased the incidence of not only mastitis, but also foot
disease, reproductive disorders, and overall avoidable distress as well.' On December
17, 1999, European Union Ministers approved the European Commission's
permanent ban on the use of rBST and the sale of dairy products containing milk
from treated cows.67
Not onlyhas the concern in other nations heightened fear in American consumers,
Oct. 23, 1998, at All, LEXIS, News Library, TSTAR File.
58. See id.
59. Id.
60. Id.
61. Id.
62. Health Canada Rejects Bovine Growth Hormone in Canada, CANADIAN CORP.
NEwswRE, Jan. 14, 1999, LEXIS, News Library, CCN File (noting that, even though the
Human Health Committee has yet to uncover significant human health concerns, the risks to
the health of the animals is enough to ban the use altogether).
63. Cerro, supra note 1, at 183 n.145.
64. Peter Gruner, Come Clean on Secret GM Milk Hormone Trials, Ministers Told,
EVENING STANDARD (London), June 23, 1999, at 25, LEXIS, News Library, ESTAND File.
65. See Stauber v. Shalala, 895 F. Supp. 1178, 1192-93 (W.D. Wis. 1995) (noting the
initial findings of the FDA); cf. D.G. McClary et al., The Effects of a Sustained-Release
Recombinant Bovine Somatotropin (Somidobove) on Udder Health for a Full Lactation, 77
J. DAIRY SCL 2261, 2270 (1994).
66. Consumers Mop Up in Milk War: An Amazing U-Turn Has Repelled American
Hormone-Treated Milk, GuARDIAN (London), July 22, 1999, at 20, LEXIS, News Library,
GUARDN File [hereinafter Consumers Mop Up]. Even the label placed on Posilac by the
manufacturer indicates that injections ofrBST may cause a variety of serious health problems
in the cows. Int'l Dairy Foods Ass'n v. Amestoy, 92 F.3d 67, 78 (2d Cir. 1996) (Leval, J.,
dissenting); see also Ben &Jerry's, supra note 7, at http://www.benjerry.com/bgh/index.html.
67. Likewise, since the FDA's approval of Monsanto's Posilac in 1993, no other
industrialized nation has licensed Posilac. Green, supra note 55, at 18.
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but it has called into question the reaction of the FDA to these countries' actions."
The FDA's mission statement specifically states that the agency will "participate
through appropriate processes with representatives of other countries to . . .
harmonize regulatory requirements, and achieve appropriate reciprocal
arrangements."'
Opponents of rBST criticize the FDA for not fully considering the actions taken
by foreign countries and issues such as international trade when that is a duty
enumerated in the FDA's mission statement."0 These opponents contend that, if the
FDA had considered these issues, the ultimate decision regarding labeling may have
been different."'
B. Human Health Concerns
Despite the numerous reassurances given by FDA officials' and other government
officers,' there is evidence of concern among the American public. 4 When Amestoy
was decided, the court dismissed consumer concern as mere "curiosity" and did not
view that interest as "substantial." 5 The court also indicated that Vermont would
have been unable to refute successfully the FDA's findings." Although there is little
hard evidence, given that the drug was developed, approved, and used too recently
to have any compelling long-term studies, more research has surfaced justifying
consumer concern and doubts and questioning the thoroughness and care with which
the FDA conducted its studies.
68. See LaraBeth Winn, SpecialLabelingRequirementsfor GeneticallyEngineeredFood:
How Sound Are the Analytical Frameworks Used by FDA and Food Producers?, 54 FOOD &
DRUG L.J. 667, 678-79 (1999).
69. Id. at 679 (quoting FDA, FDA's Mission, at www.fdagov.opaom/morechoices/
mission.html (last modified Oct. 19, 1998)).
70. See id.
71. See id.
72. "'[T]he public can be confident that milk and meat from rBST-treated cows is safe to
consume." Cerro, supra note 1, at 176 (citing Press Release, Susan M. Cruzan, FDA Approves
New Animal Drug Sometribove (Nov. 5, 1993) (quoting FDA Commissioner David A.
Kessler), http://www.fda.gov/bbs/topics/NEWS/NEW00443.html).
73. "Milkfromcows given supplemental bovine somatotropin is the same as anyothermilk
." Id. at 176 (quoting former U.S. Surgeon General C. Everett Koop).
74. As many as three-fourths of the people are said to be concerned about genetically
engineered foods. Cerro, supra note 1, at 169 (citing William B. Lacy et al., Emerging Trends,
Consequences, and Policy Issues in Agricultural Biotechnology, in BOVINE SOMATOTROPIN
& EMERGING IssuEs 3,5-6 (Milton C. Hallberg ed., 1992)). Another indication of the growing
concern among consumers is the increase in sales of organic products. Organic farmers in
Minnesota claimed at one point that their sales have more than quadrupled since 1993 when
the hormone was approved. Id.
75. Int'l Dairy Foods Ass'n v. Amestoy, 92 F.3d 67,73 (2d Cir. 1996).
76. Id. at 74.
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1. Insulin Growth Factor-One and Its Potential Effects
There is much concern that the use of rBST increases levels of Insulin Growth
Factor-One ("IGF-l") in the milk. Studies conducted by the FDA concluded that
IGF-1 does increase but that the effects on humans are harmless.' According to the
Council of Scientific Affairs, a subgroup of the American Medical Association, these
assurances were based upon minimal data and further research should have been
conducted before the FDA approved the hormone's use.78 Contradicting studies have
emerged since the FDA's assertion regarding the effects of IGF-1. One study
indicates that IGF-1 stimulates growth ofintestinal cells-possiblyleadingto the risk
of colon cancer.79 Other studies link increased levels of IGF-1 consumption with
increased risks of breast and gastrointestinal cancers." Although more evidence is
needed, the potential risks identified by various studies have some scientists
demanding that they should continue extensively researching rBST in order to
accurately assess these risks before the FDA approves the hormone's use."'
2. Possibilities of Antibiotic Residue
Perhaps the greatest fear of antihornone advocates focuses not on the higher
incidence of pus and bacteria in the milk 2 but on the powerful antibiotics injected in
cows to treat the increase of pus, mastitis, and other diseases.' Long-term exposure
to even 'small amounts of antibiotics can lead to the development of resistance in
humans." The Center for Disease Control ("CDC") recently issued numerous
warnings for encephalitis and streptococcus pneumoniae bacteria that cause
meningitis, pneumonia, and other diseases in which antibiotics are ineffective,"
77. Council on Scientific Affairs, Am. Med. Ass'n, Biotechnology and the American
Agricultural Industry, 265 JAMA 1429, 1433 (1991).
78. Id.
79. Michael Hansen et al., Potential Public Health Impacts of the Use of Recombinant
Bovine Somatotropin in Dairy Production, CONSUMERUNION, I (Sept. 1997) (citing Susan
S. Devesa et al., Recent Cancer Trends in the United States, 87 J. NAT'L CANCER INST. 175,
175-82 (1995) (pointing out that colon cancer is the third most common cancer mortality in the
United States)), at http://www.consumer.org/food/bgh-codex.htmI.
80. John Grogan & Cheryl Long, The Problem with Genetic Engineering, ORGANIC
GARDEN G, Jan. & Feb. 2000, at 42,46; see also Samuel S. Epstein, Monsanto's Genetically
Modified Milk Ruled Unsafe by the United Nations, PR NEWSWIRE, Aug. 18, 1999, LEXIS,
News Library, PRNEWS File (noting a finding by the public health committee commissioned
by the European Commission that showed an increase in "highly potent variants" of IGF-l and
concluding that this increase posed major risks of breast and prostate cancer).
81. Hansen et al., supra note 79, at http://www.consumer.org/food/bgh-codex.html.
82. PURE FOOD CAMPAiGN, FOUND. OFECON. TRENDs, RBGH WARNiNG AND WHAT YOU
CAN Do TODAY, http://www.holisticmed.com/bgh/bst-wam.txt (last visited Jan. 7, 2001)
(accrediting this knowledge to the FDA).
83. Id.
84. Susan Okie, Experts Urge Steps to Stem Antibiotic Resistance, WASH. POST, Aug. 26,
1997, at 7.
85. Id.
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callingthe developingresistance to these antibiotics "'a majorpublic health crisis."""
The CDC has determined there is a link between the injection of antibiotics into
animals' and humans' growing resistance to antibiotics.'
The FDA takes "precaution" by "spot checking" 500 samples of milk a year for
twelve drugs in order to discard any milk with increased levels of these antibiotics."
While this should help stamp out consumers' concern over antibiotic residue in their
milk, there are reasons why this "spot checking" may be unsuccessful in alleviating
these fears. Manufacturers use more than twelve types of drugs in treating cows and
the checks do not detect all of these antibiotics.89 Also disconcerting is the increase
by the FDA in the allowable levels of antibiotics in milk from one part per billion to
one part per million.' ° Therefore, the fact that the FDA requires "spot checking" for
antibiotics does little to ease consumers' fears considering the higher levels of
antibiotics allowed and the possibility of drugs going undetected.
3. Mad Cow Disease
The FDA has looked into the increase in IGF-1 and the possibilities of antibiotic
residues in milk treated with rBST. The use of this hormone, however, may cause
another serious risk to human health that the FDA has yet to address-the potential
for a cow treated with rBST to develop the debilitating disease bovine spongiform
encephalopathy, commonly known as "mad cow" disease.9' Mad cow disease attacks
the nervous system in cows and "eats microscopic sponge-like holes in a cow's
brain."'92 Critics are concerned that the increased protein needs in cows treated with
rBST will, in turn, increase the use of "high protein feed"-a possible cause of the
disease.93 The protein supply in the feed typically comes from ground up animal
meat-ultimately turning cows into carnivores." One possible way by which cows
contract mad cow disease is from eating "fodder containing processed flesh,
especially nerve tissue, of sheep and other animals." 95 Scientists believe there is a
direct link between Creutzfeldt-Jakob disease, a disease with similar effects in
humans, and eating meat from cows with mad cow disease.' There have notbeen any
reliable studies done on the potential for rBST-treated cows to develop mad cow
86. Aboulafia, supra note 5, at 630 (quoting Tony Hiss, How Now, Drugged Cow:
Biotechnology Comes to Rural Vermont?, HARPER'S MAG., Oct. 1994, at 80, 82).
87. Id. at 629-30.
88. Hansen et al., supra note 79, 2, at http://www.consumer.org/food/bgh-codex.html.
89. Id.
90. See Betty Martini, Danger in Dairy, ENVrL TIMEs, http://www.lisco.coml
FranceTM/manipulationgenetique.html (last visited Oct. 29, 2000).
91. Emily Marden, Recombinant Bovine Growth Hormone and the Courts: In Search of
Justice, 46 DRAKE L. REv. 617,624 (1998).
92. Questions and Answers on Mad Cow Disease, TORONTO SUN, Mar. 30, 1996, at 16,
LEXIS, News Library, TORSUN File [hereinafter Questions and Answers].
93. Marden, supra note 91, at 624.
94. David Ehrenfeld, Letterto Editor, BlameFactoryFarmingforMad-CowDisease, N.Y.
TirEs, Jan. 16, 1996, at A16. Dr. Ehrenfeld is a professor of Biology at Rutgers University.
95. Id.
96. See Questions and Answers, supra note 92, at 16.
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disease since the FDA has chosen not to address this particular concern.7
C. Calling the FDA into Question
Judge Leval expressed disbeliefin the majority's opinion that consumers' concerns
about the findings of the FDA are unfounded and unreasonable." He cited nmierousposs'ble reasons why people may have legitimate concerns despite the reassurances
of the FDA." Leval's dissent also noted that inadequate time and money given to
testing, pressures from industry, unmanageable population samples, and inadequate
advancement of new scientific techniques can all contribute to why a government
agency may be unsuccessful in determining health effects. " Judge Leval pointed to
a study conducted by the General Accounting Office ("GAO), 01 examining various
drugs and their effects, which surfaced only after the approval by the FDA and use
by the public." The GAO discovered 102 of the 198 drugs approved by the FDA
between 1976 and 1985 had serious postapproval risks."03 For some drugs, these risks
included adverse reactions "leading to hospitalization,.. . severe or permanent
disability, or [possibly even] death."'" Judge Leval also cited his own experiences
with cigarette smoking to illustrate how health hazards can surface even after a
product is presumed safe.' All of these reasons substantially undermine the notion
that the FDA's assurances relegate any consumer concern to mere "curiosity."
Since Amestoy, however, even more compelling reasons for consumer skepticism
surrounding the FDA's findings have surfaced. On December 15, 1998, the Center
for Food Safety ("CFS") and two dozen other consumer groups filed a petition to
reverse the FDA's approval ofrBST.1° This petition came in response to "mounting
evidence" against the FDA's findings, including studies from Canada contradicting
the studies performed by the FDA." The FDA conducted a study on rats before its
approval of the hormone and concluded that "no toxicologically significant changes
97. See Consumers Mop Up, supra note 66, at 20.
98. Int'l Dairy Foods Ass'n v. Amestoy, 92 F.3d 67, 76 (2d Cir. 1996) (Leval, J.,
dissenting) (calling the majority's proposition "alarming and dangerous; at the very least,..
extraordinarily unrealistic").
99. Id. at 77.
100. Id.
101. Id. (citing GAO Report, FDA DrugReview: PostapprovalRisks, 1976-85,1990 GEN.
ACCT. OFF. REP. 1, 2-3). Congress requested this study after numerous attempts by Senator
Patrick J. Leahy, Chairman of the Senate Agriculture Committee, to get the FDA to respond
to his letters requesting information regarding the FDA's rBST testing methods. See Aboulafia
supra note 5, at 614.
102. Amestoy, 92 F.3d at 77 (Leval, ., dissenting).
103. Id. (citing GAO Report, FDA DrugReview: PostapprovalRisks, 1976-85,1990 GEN.
AccT. OFF. REP. 1, 2-3).
104. Id.
105. Id.
106. Legal Challenge Filed with FDA to Remove Monsanto's BGH from the Market, at
http://www.purefood.org/rBGH/remove.cfm (Dec. 15, 1998) [hereinafter Legal Challenge
Filed with FDA].
107. Id.
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were noted... in rats [that were] administered [BGH] orally."' 8' Providing the
findings of this study alone as its reason, the FDA did not mandate any human
toxicological tests-a customary practice when approving a veterinary drug."
Health Canada filed a report directly contradicting the findings of the FDA studies.
It found other studies that indicated the rats did absorb the hormone and that as many
as twenty to thirtypercent of the rats developed "distinct immunological reactions .".0
The Health Canada report also verified that cysts developed on the thyroids of treated
rats and "infiltrated the prostate" in some rats.' Michael Hansen, a researcher with
Consumer Policy Institute, argues that these studies should have "triggered a full
human health review, including assessment of potential carcinogenic and
immunological effects.""..2 There is some evidence indicating that the results in the
original studies cited by the FDA were not thoroughly considered by the FDA
because Monsanto conducted the studies, and the FDA based their assumptions of
safety solely on the summaries of those studies."' As a result of this evidence, the
CFS and other consumer interest groups have alleged fraud on the part of the FDA
and Monsanto." 14
Allegations of FDA conflicts of interest also validate consumer concern and
enhance a state's interest in mandating labeling. Evidence of a significant overlap of
officials and interested parties between Monsanto and the FDA has emerged since the
court in Amestoy discounted any mistrust in the FDA. Monsanto's chief researcher
ofrBST, Margaret Miller, was hired by the FDA as their deputy director of the Office
of New Animal Drugs."5 Her role at the FDA was essentially to review her own
research."6 While on board, Miller was behind the increase of allowable levels of
antibiotic residue in milk." 7 Michael Taylor, a powerful agent in the FDA that
oversaw the approval process of rBST, was also Monsanto's attorney."'
108. Id. (alteration in original).
109. Id.
110. Id.
111. Id.
112. Id.
113. Id.; see also Grogan & Long, supra note 80, at 43 (stating that the FDA requires only
assurances from manufacturers that genetically engineered foods are safe).
114. Legal Challenge Filed with FDA, supra note 106, at http://www.purefood.org/rBGH/
remove.cfi.
115. Aboulafla, supra note 5, at 623.
116. Martini, supra note 90, http:/www.lisco.comFranceTM/manipulationgenetique.html;
see also Morris, supra note 56, at 306 (noting former Monsanto employee Margaret Miller's
clearance in a conflict of interest for her work with rBST at the FDA before she moved on to
become a rapporteur at the Joint Expert Committees on Food Additives ("JECFA")).
117. See Martini, supra note 90, http://www.lisco.com/FranceTM/manipulation-genetique.
html (alleging that the increase was 100 times).
118. See id., http://www.lisco.comFranceTM/manipulation-genetique.htnl; see also
Aboulafia, supra note 5, at 624 (identifying Michael Taylor as the FDA's deputy commissioner
for policy). Conflicts of interest have been uncovered not only in the FDA, but also in
international organizations reviewing rBST such as the JECFA, a subcommittee of the Food
and Agriculture/World Health Organizations as well. In his report, Samuel S. Epstein claimed
that the JECFA and other organizations are packed with "unelected, unaccountable...
regulatory officials and industry consultants with no expertise in public health, preventive
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Recently, a citizens group entitled Council of Canadians ("CoC") raised "serious
questions about the objectivity of the expert panels.'. 19 CoC asserted that Rejeanne
Gougeon, a human-safety panelist, consulted for Monsanto on the hormone." The
risk of undue influence from the overlap of officials prompted U.S. Senator Eugene
Whelan to testify that he would not place weight on any of the testimony from these
organizations on the safety of the hormone in hearings conducted by the Senate.21
D. Consumer Concern Sufficient for Article III Standing
Around the same time parties were preparing arguments regarding Vermont's
mandatory labeling law in Amestoy, the U.S. District Court for the Western District
of Wisconsin was hearing Barnes v. Shalala,' an action brought to suspend the
FDA's approval of rBST until more tests couldbe conducted. In a hearing regarding
the defendants' motion to dismiss for lack of subject matterjurisdiction, Judge Crabb
had to determine whether the plaintiffs had Article I standing under either the Food,
Drug and Cosmetics Act ortheNational EnvironmentalPolicyAct.'23 Three elements
must be satisfied in order to have standing under Article III of the Constitution: (1)
an injury or threat of injury, (2) causation traceable to the defendant's conduct, and
(3) likelihood that a decision in the plaintiff s favor would provide redress. 24 To
satisfy the first element, the injury or threat of injury mustbe "real and immediate!"'
and "concrete and particularized" going beyond "intellectual or academic
curiosity.""l
Two of the plaintiffs were consumers of milk and milk products and alleged that
their harm was the inability to consume dairy products due to the lack of labeling and
impossibility of choosing products from untreated cows.2 These plaintiffs also
expressed a sincere fear that consuming products from cows treated with rBST would
be harmful to their health.'28
The defendants in Shalala attempted to dismiss consumer fear as speculative and
unrealistic and argued that such fear was nothing that the voluntary labeling of milk
allowed by the FDA could not remedy." Judge Crabb, however, sided with the
medicine, and carcinogenesis." Epstein, supra note 80. Epstein's report cited overlap of
regulatory and industry officials within these committees and discussed the resulting problems
in objectivity in the rBST reviews. Id.
119. Morris, supra note 56, at 306 (internal quotes omitted).
120. Id.
121. Id.
122. 865 F. Supp. 550,556 (W.D. Wis. 1994).
123. Id. at 554, 558.
124. Id. (citing Family & Children's Ctr., Inc. v. Sch. City of Mishawaka, 13 F.3d 1052,
1058 (7th Cir. 1994) (citing Lujan v. Defenders of Wildlife, 504 U.S. 555 (1992))).
125. Id. at 558 (quoting Schmidling v. City of Chicago, I F.3d 494,498 (7th Cir. 1993)).
126. Id. (quoting Family & Children's Ctr., Inc. v. Sch. City of Mishawaka, 13 F.3d 1052,
1058 (7th Cir. 1994)).
127. Id.
128. Id.
129. Id.
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consumer-plaintiffs 3 ' and found their alleged injuries sufficient.' Judge Crabb
noted that voluntary labeling, while able to mitigate some of the harm of not knowing
whether the product contained milk from treated cows, is in no way complete
redress.' Even though the court here denied a chance for all concerns and fears to
be heard in a court of law, this case makes it easier for plaintiffs wishing to bring
claims based on consumer fear to gain standing.
E. Why Mandatory Labeling?
Even if a state were successful in proving the legitimate and substantial nature of
its interest in consumer concern, there is still a question left in the four-part Central
Hudson analysis that the court in Amestoy did not consider. This involves whether
labeling is necessary in order to directly advance the state's interest. There is
evidence that mandatory labeling is the best option to remedy the concerns of the
public with regard to their abilityto make conscious choices aboutthe foods theybuy.
In the spring of 1999, Congress received 500,000 signatures calling for mandatory
labeling of all genetically altered foods.' Similarly, the FDA faces two recent
lawsuits demanding labeling. 3 Some people do not believe that mandatory labeling
is necessary given the voluntary labeling allowed by the FDA's interim guidance.
Recently, however, consumers, retailers, and officials have felt the effects of the lack
of labeling requirements on the ability of consumers to decide for themselves.
Richard Wolfson, the chairman of Canada's Consumer Right to Know Campaign,
recognized that mandatory labeling was the only way to sufficiently trace and
measure anyhealth effects and the only way to ensure that consumers were protected
and had the right to choose.'35 Following similar logic, Japan has required labeling
of genetically altered foods. 36
People with religious or moral reasons for not wanting to consume products from
treated cows will find it virtually impossible to identify and eliminate such products
130. Not all of the plaintiffs in the case were successful in establishing Article III standing.
The court dismissed the actions of the plaintiffs known as the "sellers of dairy products"
(various wholesalers, store owners, and restaurant owners), stating that their allegations were
based on too much speculation. Id. Likewise, the plaintiffs that were health care professionals,
veterinarians, and counselors found their case dismissed for unsubstantiated injuries. Id. at 561.
The Foundation of Economic Trends, a not-for-profit organization, claimed a drain ofresources
as its injury, but the court dismissed this claim as well. Id. The only other plaintiffs to emerge
successful in not getting their claim dismissed were the dairy farmers. Id. at 560.
131. Id.
132. Id. (stating that the complete cure for plaintiffs' want is a change in the FDA's
approval). However, the insufficiency of voluntary labeling in helping consumers make
informed decisions noted by Judge Crabb, and her opinion that the fear of consuming products
from hormone treated cows is sufficient for standing, parallel the arguments made by the
district court in Amestoy and Judge Leval.
133. See Grogan & Long, supra note 80, at 43.
134. Id.
135. Id.
136. Id.
[Vol. 76:785
GOT "HORMONE-FREE" MILK?
given the existence of dairy in so many food items.'37 Two major natural-foods
supermarket chains are facing some difficulties after they announced the plan to "rid
their shelves of products that contain biotech ingredients."'3 Manufacturers are not
required to label whether their ingredients contain any geneticallymodifiedproducts,
including the use of rBST, making the goal of these supermarkets difficult to
accomplish for years.'39 Margaret Whittenberg, vice-president of Whole Foods, a
chain of 103 stores in twenty-two states, recognized an "absolute anger" among her
customers that they did not know all the ingredients of the foods they wished to
purchase."4 Wild Oats, another maj orhealth-food supermarket attempting to rid itself
of genetically modified foods, is facing similar difficulties produced by a lack of
labeling.' 4' Until these chains are successful, citizens will likely continue to consume
genetically engineered foods against their will despite their best efforts not to do so.
The actions of Monsanto exemplify the usefulness of mandatory labeling laws in
combating pressures applied by large, powerful corporations. In the 1980s alone,
Monsanto invested an estimated one-half billion dollars towards developing the
hormone.'42 With such an enormous investment early on, Monsanto had a lot to
lose-especially if consumers opted to buy products not made with milk taken from
a treated cow. Brian Tokar, a professor of ecology at a small Vermont college,
accused Monsanto of issuing threats to sue some small dairy manufacturers if they
voluntarily engaged in any advertising that their milk was free of the rBST
hormone."" Monsanto actually levied suit against two dairy manufacturers for
labeling their products rBST-free and wrote letters to 2000 other manufacturers
threatening to sue them if they did the same.'" Monsanto, backed by the FDA, stated
that to label "rBST-free" is misleading because there was no reported incidence of
rBST existing in the milk itself.4" Needless to say, threats issued by a large, powerful
company, regardless if they attack specific language, maybe enough to stifle labeling
by smaller participants in the dairy industry. Allowing states to mandate particular
labeling, including the FDA's qualified statement that rBST is safe, would eliminate
such problems and strip Monsanto of its ability to use intimidation to discourage
voluntary labeling.
III. STATE REACTIONS
Despite the holding in Amestoy, some states' legislators are proposing mandatory
labeling laws in their states in response to concern among their citizens. For example,
New York Assemblyman McEneny, along with five other members of the Assembly,
137. Id. at 46-47.
138. Louise Branson, Backlash Grows in US Against GMFoods, STRAITS TIMES (Sing.),
Jan. 6,2000,2000 WL 2962540.
139. Id.
140. Id.
141. Id.
142. Aboulafia, supra note 5, at 606.
143. Brian Tokar, Monsanto: A Checkered History, 28 ECOLOGIsT 254, 258 (1998).
144. Aboulafia, supra note 5, at 618.
145. Id. at 617.
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introduced a bill requiring mandatory labeling on February 1, 2001.146 There are
forty-four cosponsors listed on the bill. 47 The bill states the reasoning as follows:
The Legislature hereby finds and declares that there has been a substantial public
debate concerning the possible health and safety effects ofmilk and milk products
produced from cows injected with Recombinant Bovine Somatotropin .... There
is also substantial evidence that when food or food products... are enhanced by
the influence of foreign substances... there can be a health and safety impact
upon [the consumers]. The Legislature also finds and declares that although at
present the exact impact, if any, of the direct link between [rBST] and disease or
affliction is undetermined, at their inception the enhancement of food or food
product such as milk or other naturally produced human consumables, by the
influence of foreign other substances ... were equally undetermined, only to be
found later to cause a significant health and safety impact as well as a direct link
to human disease or affliction. 14
The bill proposes that mandatory labeling will best serve the interests of the
citizens of New York by allowing them to determine which milk and milk products
were produced from cows treated with rBST.'49 Section 266-2 of the bill expresses
that labeling all dairy products is the "most prudent and appropriate way to inform its
citizens'""'--disputing the argument that voluntary labeling is enough to allow
consumers to make educated purchases.
Similarly, on February 10, 2000, Rhode Island representatives responded to the
controversy surrounding rBSTbyproposing abill that would require labeling of dairy
products as well. 5 ' This bill calls for clear and conspicuous labeling on the container
of any product containing milk derived from cows treated with rBST and imposes
monetary fines for violations. 52 If passed, the bill will become an act to take effect
as early as June 30, 20012"3 Although these states are undoubtedly going to have to
litigate these proposals if and when they become law, the mere fact that the Second
Circuit opinion in Amestoy does not curtail their efforts is an encouraging sign that
the issue of mandatory labeling is still prevalent today.
CONCLUSION
More state legislators are listening to the valid concerns of their constituents and
are attempting to forge through the door left open by the appellate court in Amestoy.
New York and Rhode Island are attempting the very legislation that an appellate court
struck down in Vermont. New York legislators state the exact same reasons for
146. See Assemb. 3586,2001 Leg., 224th Ann. Sess. (N.Y. 2001), WL 2001 NY A.B. 3586
(proposing to amend the general business law by adding Article 16-A, which includes
mandatory labeling laws).
147. Id.
148. Id. § 266-1.
149. Id. § 266-2.
150. Id.
151. H.R.7511,1999 Leg., 1999-2000 Legis. Sess., § 2-31.1 (R.I. 2000), WL 1999 RI H.B.
7511.
152. Id.
153. Id.
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issuing mandatory labeling laws but, if taken to court, will likely have more
compelling evidence to support their case and, therefore, a better chance of meeting
the standard set outby the court in Amestoy. Since that case, much more evidence and
information regarding the effects ofrBST on cow andhumanhealth and questionable
activity on the part of the FDA have emerged. If the states are successful in passing
the first part of the test set out in Central Hudson, they still face the question of
whether mandatory labeling is essential to the advancement of their interests.
.The decision of any court to uphold mandatory labeling laws passed by states will
have a great impact on far more than just the dairy products sitting on grocery
shelves. There is considerable evidence indicating that mandatory labeling is
necessary to maximize the choice consumers have over the products they purchase.
Mandatory labeling may also be a state's solution to the problems surrounding the
influence Monsanto has exerted over the dairy industry and federal agencies. As long
as a state is careful in its choice of words on the label-asserting truthful, non-
misleading information-there is quite possibly enough evidence for it to emerge
victorious in convincing the court that mandatory labeling appeases a legitimate
consumer concern, places the choice in the proper hands, and is not too restrictive in
accomplishing its goals.

